As per the terms of the option agreement, Celtic Therapeutics has an exclusive option to acquire and license rights to Resolvyx’s RX-10045, in all eye indications.
Additionally, Celtic Therapeutics may also license rights to and develop another Resolvyx compound in a topical formulation for ophthalmic indications.
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases.
RX-10045, a resolvin administered as a topical eye drop, produced dose-dependent, significant improvement on the primary endpoints for both the signs and symptoms of dry eye, and was generally shown to be safe and well tolerated in a placebo-controlled Phase II study.
Celtic Therapeutics co-founder and managing general partner Peter Corr said that Celtic Therapeutics was excited to invest in Resolvyx’s technology.
"With the potential for improved efficacy, a much faster onset of action, an improved tolerability profile, and a patent estate, we believe RX-10045, if approved, would represent an important step forward in the treatment of this condition," Corr said.
Resolvyx chief operating officer Jamie Nichols said that they were delighted to be allied with Celtic Therapeutics in maximising the therapeutic potential of Resolvins to treat dry eye syndrome and other eye disease.
Celtic Therapeutics co-founder and managing general partner Stephen Evans-Freke said that their investment in Resolvyx and RX-10045 demonstrates Celtic Therapeutics’ focus on new classes of biologic or small molecule therapeutics that hold the promise of medical advances compared to currently available treatment options.